Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab vedotin in CD30-positive cutaneous T-cell lymphoma
NCT05442554Phase 4Completed
- Sponsor
- Takeda
- Start
- Nov 2022
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of brentuximab vedotin in cutaneous T-cell lymphoma (CTCL), sponsored by Takeda. Primary endpoint: Overall Response Rate Lasting at Least 4 Months. Started Nov 2022; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT05442554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05442554.